Cargando…

Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease

BACKGROUND: This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep dysfunction in patients with Parkinson’s disease (PD). METHODS: PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner for 12 weeks while maintainin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Weidong, Kwak, Shin, Li, Guoyan, Chen, Yiyun, Cai, Dingfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733743/
https://www.ncbi.nlm.nih.gov/pubmed/23890176
http://dx.doi.org/10.1186/1749-8546-8-14
_version_ 1782279398319194112
author Pan, Weidong
Kwak, Shin
Li, Guoyan
Chen, Yiyun
Cai, Dingfang
author_facet Pan, Weidong
Kwak, Shin
Li, Guoyan
Chen, Yiyun
Cai, Dingfang
author_sort Pan, Weidong
collection PubMed
description BACKGROUND: This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep dysfunction in patients with Parkinson’s disease (PD). METHODS: PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner for 12 weeks while maintaining other anti-parkinsonism medications (e.g., dopaminergic agent, dopamine agonist) unchanged. Additional participants without sleep disturbance or PD served as controls. The changes in detrended fluctuation analysis (DFA) of physical activity with respect to diurnal activity (DA), evening activity (EA), nocturnal activity (NA), Parkinson’s disease sleep scale (PDSS) score and unified Parkinson’s disease rating scale (UPDRS) score were evaluated every 4 weeks during the 12-week YXQN intervention period and again at week 16. RESULTS: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study. Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively. CONCLUSION: YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.
format Online
Article
Text
id pubmed-3733743
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37337432013-08-06 Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease Pan, Weidong Kwak, Shin Li, Guoyan Chen, Yiyun Cai, Dingfang Chin Med Research BACKGROUND: This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep dysfunction in patients with Parkinson’s disease (PD). METHODS: PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner for 12 weeks while maintaining other anti-parkinsonism medications (e.g., dopaminergic agent, dopamine agonist) unchanged. Additional participants without sleep disturbance or PD served as controls. The changes in detrended fluctuation analysis (DFA) of physical activity with respect to diurnal activity (DA), evening activity (EA), nocturnal activity (NA), Parkinson’s disease sleep scale (PDSS) score and unified Parkinson’s disease rating scale (UPDRS) score were evaluated every 4 weeks during the 12-week YXQN intervention period and again at week 16. RESULTS: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study. Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively. CONCLUSION: YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants. BioMed Central 2013-07-27 /pmc/articles/PMC3733743/ /pubmed/23890176 http://dx.doi.org/10.1186/1749-8546-8-14 Text en Copyright © 2013 Pan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Pan, Weidong
Kwak, Shin
Li, Guoyan
Chen, Yiyun
Cai, Dingfang
Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
title Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
title_full Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
title_fullStr Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
title_full_unstemmed Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
title_short Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
title_sort therapeutic effect of yang-xue-qing-nao granules on sleep dysfunction in parkinson’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733743/
https://www.ncbi.nlm.nih.gov/pubmed/23890176
http://dx.doi.org/10.1186/1749-8546-8-14
work_keys_str_mv AT panweidong therapeuticeffectofyangxueqingnaogranulesonsleepdysfunctioninparkinsonsdisease
AT kwakshin therapeuticeffectofyangxueqingnaogranulesonsleepdysfunctioninparkinsonsdisease
AT liguoyan therapeuticeffectofyangxueqingnaogranulesonsleepdysfunctioninparkinsonsdisease
AT chenyiyun therapeuticeffectofyangxueqingnaogranulesonsleepdysfunctioninparkinsonsdisease
AT caidingfang therapeuticeffectofyangxueqingnaogranulesonsleepdysfunctioninparkinsonsdisease